Prudential Financial Inc. grew its holdings in shares of Amedisys Inc (NASDAQ:AMED) by 20.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 59,979 shares of the health services provider’s stock after purchasing an additional 10,118 shares during the period. Prudential Financial Inc. owned approximately 0.19% of Amedisys worth $7,495,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Janney Montgomery Scott LLC bought a new stake in shares of Amedisys in the 2nd quarter valued at $818,000. Aperio Group LLC increased its stake in shares of Amedisys by 5.1% in the 2nd quarter. Aperio Group LLC now owns 18,079 shares of the health services provider’s stock valued at $1,545,000 after acquiring an additional 882 shares in the last quarter. First Trust Advisors LP increased its stake in shares of Amedisys by 235.7% in the 2nd quarter. First Trust Advisors LP now owns 51,502 shares of the health services provider’s stock valued at $4,401,000 after acquiring an additional 36,161 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of Amedisys in the 2nd quarter valued at $517,000. Finally, Sei Investments Co. increased its stake in shares of Amedisys by 762.0% in the 2nd quarter. Sei Investments Co. now owns 123,582 shares of the health services provider’s stock valued at $10,562,000 after acquiring an additional 109,246 shares in the last quarter. Institutional investors own 92.39% of the company’s stock.
Shares of AMED stock opened at $130.30 on Friday. The firm has a market cap of $4.32 billion, a price-to-earnings ratio of 41.06, a price-to-earnings-growth ratio of 2.02 and a beta of 1.29. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.06 and a quick ratio of 1.06. Amedisys Inc has a 12 month low of $49.80 and a 12 month high of $140.91.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Monday, October 29th. The health services provider reported $0.95 EPS for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.18. The business had revenue of $417.34 million during the quarter, compared to analyst estimates of $411.05 million. Amedisys had a net margin of 5.39% and a return on equity of 23.27%. Amedisys’s quarterly revenue was up 11.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.56 EPS. Analysts forecast that Amedisys Inc will post 3.58 EPS for the current year.
Several analysts have recently weighed in on AMED shares. SunTrust Banks lifted their price objective on shares of Amedisys to $130.00 and gave the company a “buy” rating in a research note on Thursday, October 11th. Bank of America set a $139.00 price objective on shares of Amedisys and gave the company a “buy” rating in a research note on Tuesday, September 18th. BidaskClub lowered shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 16th. Benchmark upgraded shares of Amedisys from a “hold” rating to a “buy” rating and set a $125.00 price objective for the company in a research note on Tuesday, October 30th. Finally, Craig Hallum lowered shares of Amedisys from a “buy” rating to a “hold” rating and lowered their price objective for the company from $116.00 to $104.00 in a research note on Friday, October 26th. Six equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company. Amedisys currently has a consensus rating of “Buy” and a consensus price target of $107.08.
In other Amedisys news, COO Christopher Gerard sold 7,892 shares of the business’s stock in a transaction on Friday, November 9th. The shares were sold at an average price of $119.02, for a total transaction of $939,305.84. Following the completion of the sale, the chief operating officer now owns 29,429 shares in the company, valued at approximately $3,502,639.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jake L. Netterville sold 3,394 shares of the business’s stock in a transaction on Friday, November 16th. The shares were sold at an average price of $122.86, for a total transaction of $416,986.84. Following the sale, the director now owns 75,266 shares of the company’s stock, valued at approximately $9,247,180.76. The disclosure for this sale can be found here. Insiders have sold a total of 37,486 shares of company stock valued at $4,449,649 in the last 90 days. 2.60% of the stock is currently owned by company insiders.
WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/12/08/amedisys-inc-amed-holdings-boosted-by-prudential-financial-inc.html.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Read More: Compound Annual Growth Rate (CAGR)
Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys Inc (NASDAQ:AMED).
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.